Exacerbated PI3K-AKT signalling can also occur due to loss of PTEN (a p53 transcriptional target and inhibitor of the PI3K-AKT pathway) in melanoma resistance to targeted therapy [11,27,28]. Here, PTEN is linked to melanoma.